← Leaderboards
J. Christopher Gorski
Indiana Univ-Purdue Univ At Indianapolis
$69,215
Attributed
$69,215
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $32.3K · FY2005–06$50K$37.5K$25K$12.5K$0
'05
'06
Funding mix
By agency
NIH$69,215 · 4
By mechanism
M01$69,215 · 4
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Stephen D Hall$1,925,382
- Barbara Haehner$0
- Lang Li$13,579,025
- Jude Christopher Gorski$1,202,478
- Harold G Bohlen$2,018,378
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClearance RateLiver CirrhosisDrug MetabolismLiver MetabolismClinical ResearchEnzyme ActivityCytochrome P450Patient Oriented ResearchPharmacokineticsMembrane PermeabilityMidazolamOral AdministrationHeart Disorder DiagnosisDrug Administration Rate /DurationElectrocardiographyErythromycinGastrointestinal Absorption /TransportGastrointestinal FunctionGastrointestinal SurgeryCardiovascular Disorder RiskHeart RateIntestinal Mucosa
Grant awards (6)
ORAL ERYTHROMYCIN ON QT INTERVAL IN HEALTHY SUBJECTS, PATIENTS WITH CIRRHOSIS$26,665
M01 · FY2006 · RR · contact PI
EFFECT OF CLARITHROMYCIN ON THE ORAL CLEARANCE OF BUSPIRONE IN PATIENTS WITH$5,656
M01 · FY2006 · RR · contact PI
ORAL ERYTHROMYCIN ON QT INTERVAL IN HEALTHY SUBJECTS, PATIENTS WITH CIRRHOSIS$22,973
M01 · FY2005 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO THE SYSTEMIC METABOLISM OF MIDAZOLAM$2,209
M01 · FY2005 · RR
Oral Erythromycin on QT Interval in Healthy Subjects, Patients with Cirrhosis$10,715
M01 · FY2004 · RR
Contribution of Intestinal CYP3A to the Systemic Metabolism of Midazolam$997
M01 · FY2004 · RR